Literature DB >> 10618541

Vaccines in historic evolution and perspective: a narrative of vaccine discoveries.

M R Hilleman1.   

Abstract

The sciences of vaccinology and of immunology were created just two centuries ago by Jenner's scientific studies of prevention of smallpox through inoculation with cowpox virus. This rudimentary beginning was expanded greatly by the giants of late 19th and early twentieth centuries biomedical sciences. The period from 1930 to 1950 was a transitional era with the introduction of chick embryos and minced tissues for propagating viruses and Rickettsiae in vitro for vaccines. Modern era vaccinology began about 1950 as a continuum following notable advances made during the 1940s and World War II. Its pursuit has been based largely on breakthroughs in cell culture, bacterial polysaccharide chemistry, molecular biology and immunology, which have yielded many live and killed viral and bacterial vaccines plus the recombinant-expressed hepatitis B vaccine. The present paper was presented as a lecture given(1) on August 30, 1999 and recounts, by invitation, more than five-and-half decades of vaccine research from the venue of personal experience and attainment by the author. The paper is intentionally brief and truncated with focus only on highlights and limited referencing. Detailed recounting and referencing are given elsewhere in text references [Hilleman MR. Six decades of vaccine development - a personal history. Nat. Med. 1998;4 (Vaccine Suppl.): 507-14] and [Hilleman MR. Personal historical chronicle of six decades of basic and applied research in virology, immunology and vaccinology. Immunol. Rev. (in press)]. This narration will have achieved its purpose if it provides a background of understanding and guidelines that will assist others who seek to engage in creation of new vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618541     DOI: 10.1016/s0264-410x(99)00434-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

Review 1.  Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections.

Authors:  Maurice R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

2.  Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.

Authors:  Li-Mei Chen; Gabriel Briones; Ruben O Donis; Jorge E Galán
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 3.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

4.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Authors:  Deepak B Salunke; Nikunj M Shukla; Euna Yoo; Breanna M Crall; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2012-03-15       Impact factor: 7.446

5.  Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.

Authors:  Ang Lin; Danijela Apostolovic; Maja Jahnmatz; Frank Liang; Sebastian Ols; Teghesti Tecleab; Chenyan Wu; Marianne van Hage; Ken Solovay; Keith Rubin; Camille Locht; Rigmor Thorstensson; Marcel Thalen; Karin Loré
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

6.  The cellular and humoral immune response to influenza vaccination is comparable in asthmatic and healthy subjects.

Authors:  Andrea Aida Velasco-Medina; Miguel Leonardo García-León; Guillermo Velázquez-Sámano; Rosa María Wong-Chew
Journal:  Hum Vaccin Immunother       Date:  2020-05-21       Impact factor: 3.452

7.  Age predicts cytokine kinetics and innate immune cell activation following intranasal delivery of IFNγ and GM-CSF in a mouse model of RSV infection.

Authors:  Katherine M Eichinger; Erin Resetar; Jacob Orend; Kacey Anderson; Kerry M Empey
Journal:  Cytokine       Date:  2017-05-27       Impact factor: 3.861

Review 8.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

9.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.

Authors:  S M Sivakumar; Mohammed M Safhi; M Kannadasan; N Sukumaran
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330

10.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.